Goldman Sachs’s Galectin Therapeutics GALT Stock Holding History

Goldman Sachs’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,800	Closed	-$7K	–	7098
2016 Q1	$7K	Buy	+4,800	New	+$6.44K	﹤0.01%	6945
2015 Q3	–	Sell	-2,100	Closed	-$6K	–	7354
2015 Q2	$6K	Sell	2,100 -800	-28%	-$2.41K	﹤0.01%	7184
2015 Q1	$10K	Sell	2,900 -4,200	-59%	-$15K	﹤0.01%	6974
2014 Q4	$25K	Sell	7,100 -1,900	-21%	-$8.4K	﹤0.01%	6955
2014 Q3	$45K	Sell	9,000 -800	-8%	-$6.23K	﹤0.01%	6848
2014 Q2	$135K	Sell	9,800 -300	-3%	-$3.73K	﹤0.01%	6434
2014 Q1	$155K	Buy	+10,100	New	+$144K	﹤0.01%	6222

Other funds holding GALT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Goldman Sachs's GALT Position: Q1 2026 in Review

Goldman Sachs reduced its Galectin Therapeutics (GALT) stake by 40% in Q1 2026, selling an estimated $373K and leaving 184,737 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #5578.

Goldman Sachs first reported a position in GALT in Q1 2014 and has held it in 39 quarters since. The position peaked at $1.28M in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

Goldman Sachs held 184,737 shares of Galectin Therapeutics worth $515K as of Q1 2026.
Goldman Sachs sold 122,492 Galectin Therapeutics shares in Q1 2026, an estimated $373K.
Galectin Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5578 holding.
Goldman Sachs first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 39 quarters since.
Goldman Sachs's Galectin Therapeutics position peaked at $1.28M in Q4 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.